(UroToday.com) In this abstract, at the 2021 European Association of Urology (EAU) annual meeting, Dr. Cosimo De Nunzio et al. evaluate the safety of sequential Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG) therapy compared to BCG monotherapy in patients with high risk non-muscle invasive bladder cancer (MIBC). The study is entitled MITOBCG and this abstract presentation highlights the preliminary results.